Abstract
Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA antimiR) of microRNA-155, in Patients with CTCL
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have